An agreement amounting more than 500 million U.S. dollars between Greek- Swiss pharmaceutical and clinical research group Sellas Clinicals Holding and Chinese pharmaceutical conglomerate Fosun Pharma for the development and marketing of two drugs for treating diabetes and lung cancer was signed in Athens on Wednesday.
It is the first time that Greek and Chinese scientists and businessmen are joining forces in the field of healthcare, starting with two promising chemical compounds.
Addressing the signing ceremony on Wednesday, representatives of the two companies and officials noted the project's significance for scientific progress, for the benefit of patients, for the further economic development of the two firms and for the future of Sino-Greek collaboration.
Read more at Shanghai Daily.